Denali Therapeutics Inc. (DNLI) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DNLI Revenue Growth
Revenue Breakdown (FY 2020)
DNLI's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
DNLI Revenue Analysis (2015–2025)
As of May 8, 2026, Denali Therapeutics Inc. (DNLI) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, DNLI's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $335.7 million in 2020.
Revenue diversification analysis shows DNLI's business is primarily driven by Alzheimer's Disease Services (100%). With over half of revenue concentrated in Alzheimer's Disease Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARVN (-0.3% YoY), RCUS (+67.4% YoY), and KYMR (-12.6% YoY). Compare DNLI vs ARVN →
DNLI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DNLICurrent | $0 | - | - | - | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
DNLI Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-555,342,000 | - |
| 2024 | $0 | -100.0% | $0 | - | $-487,341,000 | - |
| 2023 | $330.5M | +204.7% | $330.5M | 100.0% | $-196,699,000 | -59.5% |
| 2022 | $108.5M | +122.9% | $108.5M | 100.0% | $-340,744,000 | -314.2% |
| 2021 | $48.7M | -85.5% | $48.7M | 100.0% | $-295,751,000 | -607.8% |
| 2020 | $335.7M | +1158.2% | $335.7M | 100.0% | $62.7M | 18.7% |
| 2019 | $26.7M | -79.3% | $26.7M | 100.0% | $-213,184,000 | -799.1% |
| 2018 | $129.2M | - | $129.2M | 100.0% | $-46,372,000 | -35.9% |
| 2017 | $0 | - | $-3,082,000 | - | $-90,140,000 | - |
| 2016 | $0 | - | $-1,469,000 | - | $-87,433,000 | - |
See DNLI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNLI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNLI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNLI — Frequently Asked Questions
Quick answers to the most common questions about buying DNLI stock.
Is DNLI's revenue growth accelerating or slowing?
DNLI TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DNLI's long-term revenue growth rate?
Denali Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is DNLI's revenue distributed by segment?
DNLI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.